'3+1' Mixed-ligand oxotechnetium(V) complexes with affinity for melanoma: Synthesis and evaluation in vitro and in vivo

Journal of Medicinal Chemistry

Volumn 43, Issue 14, 2000, Pages 2745-2752

  Friebe, Matthias ^a   Mahmood, Ashfaq ^a   Spies, Hartmut ^b   Berger, Ralf ^b   Johannsen, Bernd ^b   Mohammed, Ashour ^c   Eisenhut, Michael ^c   Bolzati, Cristina ^a,e   Davison, Alan ^d   Jones, Alun G ^a,f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e UNIVERSITY OF FERRARA   (Italy)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N (2 DIETHYLAMINOETHYL) 3 IODO 4 METHOXYBENZAMIDE I 123; N (2 DIETHYLAMINOETHYL) 4 IODOBENZAMIDE I 123; RADIOPHARMACEUTICAL AGENT; REDUCING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHEMICAL REACTION; COMPLEX FORMATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; IMAGING; LIPOPHILICITY; LUNG; MELANOMA; MOUSE; NONHUMAN; PKA; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SPLEEN; TUMOR LOCALIZATION;

ANIMALS; MELANOMA; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MORPHOLINES; NEOPLASM TRANSPLANTATION; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFHYDRYL COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0034644268     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000050e     Document Type: Article

References (31)

1. Marks, R. An Overview of Skin Cancers: Incidence and Causation. Cancer 1995, 75, 607-612.
2. NIH Consensus Development Panel on Early Melanoma. Diagnosis and Treatment of Early Melanoma. J. Am. Med. Assoc. 1992, 268, 1314-1319.
3. Delbeke, D. Oncological Applications of FDG PET Imaging: Brain Tumors, Colorectal Cancer Lymphoma and Melanoma. J. Nucl. Med. 1999, 40, 591-603.
4. 18F]-fluoro-2-deoxy-D-glucose Positron Emission Tomography in Staging of Regional Lymph Nodes in Patients with Cutaneous Malignant Melanoma. J. Clin. Oncol. 1998, 16, 1770-1776.
5. Ruhlmann, J.; Oehr, P.; Stegemann, G.; Steen, K.; Menzel, C.; Biersack, H. J. FDG-PET Compared to Conventional Diagnostic Methods in Malignant Melanoma. J. Nucl. Med. 1999, 40, 20P.
6. 2 Fragments. Cancer Res. 1985, 45, 3378-3385.
7. Larson, S. M. Biologic Characterization of Melanoma Tumors by Antigen-Specific Targeting of Radiolabeled Antitumor Antibodies. J. Nucl. Med. 1991, 32, 287-291.
8. Kloss, G.; Leven, M. Accumulation of Radioiodinated Tyrosine Derivatives in the Adrenal Medulla and in Melanomas. Eur. J. Nucl. Med. 1979, 4, 179-186.
9. 131I-Labeled Quinoline and Tyrosine Derivatives. Eur. J. Nucl. Med. 1981, 6, 227-233.
10. 125I-Labeled Thiouracil and Propylthiouracil in Murine Melanotic Melanomas. Br. J. Cancer 1982, 46, 538-550.
11. van Langevelde, A.; Bakker, C. N. M.; Broxterman, H. J.; Journée-de Korver, J. G.; Kaspersen, F. M.; Oosterhuis, J. A.; Pauwels, E. K. J. Potential Radiopharmaceuticals for the Detection of Ocular Melanoma. Part I. 5-Iodo-2-thiouracil Derivatives. Eur. J. Nucl. Med. 1983, 8, 45-51.
12. Giblin, M. F.; Jurisson, S. S.; Quinn, T. P. Synthesis and Characterization of Rhenium-Complexed α-Melanotropin Analogues. Bioconjugate Chem. 1997, 8, 347-353.
13. 99mTc Labeled Alpha-Melanotropin Peptides. In Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine 5; Nicolini, M., Mazzi, U., Eds.; Servizi Grafici Editorali: Padova, 1999; pp 457-463.
14. Nicholl, C.; Mohammed, A.; Hull, W. E.; Bubeck, B.; Eisenhut, M. Pharmacokinetics of Iodine-123-IMBA for Melanoma Imaging. J. Nucl. Med. 1997, 38, 127-133.
15. Mohammed, A.; Nicholl, C.; Titsch, U.; Eisenhut, M. Radioiodinated N-(Alkylaminoalkyl)-Substituted 4-Methoxy-, 4-Hydroxy-, and 4-Aminobenzamides: Biological Investigations for the Improvement of Melanoma-Imaging Agents. Nucl. Med. Biol. 1997, 24, 373-380.
16. Brandau, W.; Niehoff, T.; Pulawski, P.; Jonas, M.; Dutschka, K.; Sciuk, J.; Coenen, H. H.; Schober, O. Structure Distribution Relationship of Iodine-123-Iodobenzamides as Tracers for the Detection of Melanotic Melanoma. J. Nucl. Med. 1996, 37, 1865-1871.
17. (a) Dittmann, H.; Coenen, H. H.; Zölzer, F.; Dutschka, K.; Brandau, W.; Streffer, C. In Vitro Studies on the Cellular Uptake of Melanoma Imaging Aminoalkyl-iodobenzamide Derivatives (ABA). Nucl. Med. Biol. 1999, 26, 51-56.
18. (b) Mohammed, A.; Mier, W.; Lay, D.; Just, W.; Gorgas, K.; Lehmann, W. D.; Haberkorn, U.; Eisenhut, M. Radioiodinated N-(2-Diethylaminoethyl)benzamide Derivatives with High Melanoma Uptake; Structure-Affinity Relationship Studies, Metabolic Fate and Intracellular Localisation. Unpublished results.
19. 125I]N-(2-Piperidinylaminoethyl)4-iodobenzamide and Related Analogues as Sigma Receptor Imaging Agents; High Affinity Binding to Human Malignant Melanoma and Rat C6 Glioma Cell Lines. J. Labelled Compds. Radiopharm. 1994, 35, 242-244.
20. (b) Walker, J. M.; Bowen, W. D.; Walker, F. O.; Matsumoto, R. R.; De Costa, B.; Rice, K. C. Sigma Receptors: Biology and Function. Pharmacol. Rev. 1990, 42, 355-402.
21. 125I]-N-(N-Benzylpiperidin-4-yl)-4-iodobenzamide: A High Affinity σ Receptor Ligand for Potential Imaging for Breast Cancer. Cancer Res. 1995, 55, 3022-3027.
22. 99mTc complexation. J. Labelled Compds. Radiopharm. 1997, 40, 416-418.
23. Auzeloux, P.; Papon, J.; Masnada, T.; Borel, M.; Moreau, M.-F.; Veyre, A.; Pasqualini, R.; Madelmont, J.-C. Synthesis and Biodistribution of Technetium-99m-Labeled N-(Diethylaminoethyl)benzamide via a Bis(Dithiocarbamate) Nitridotechnetium-(V) Complex. J. Labelled Compds. Radiopharm. 1999, 42, 325-335.
24. Auzeloux, P.; Moreau, M.-F.; Papon, J.; Bayle, M.; Borel, M.; Pasqualini, R.; Madelmont, J.-C. Technetium-99m Radiolabeling of an N-Amino-alkyl-benzamide Nitrido- and Oxo-technetium Bis(Aminoethanethiol) Derivative Synthesis and Biological Results. Potential Melanoma Tracer Agents. J. Labelled Compds. Radiopharm. 1999, 42, 567-579.
25. Spies, H.; Pietzsch, H. J.; Johannsen, B. The 'n+1' Mixed-Ligand Approach in the Design of Specific Technetium Radiopharmaceuticals: Potentials and Problems. In Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine 5; Nicolini, M., Mazzi, U., Eds.; Servizi Grafici Editorali: Padova, 1999; pp 101-109.
26. Friebe, M. Amingruppentragende Technetium(V) und Rhenium-(V)-Verbindungen: Synthese und Untersuchungen von Zusammenhaengen Molekularer Eigenschaften und dem Transport über die Blut-Hirn-Schranke. Ph.D. Thesis, Technische Universität Dresden, 1999.
27. Johannsen, B.; Berger, R.; Brust, P.; Pietzsch, H.-J.; Scheunemann, M.; Seifert, S.; Spies, H.; Syhre, R. Structural Modification of Receptor-Binding Technetium-99m Complexes in Order to Improve Brain Uptake. Eur. J. Nucl. Med. 1997, 24, 316-319.
28. Braumann, T.; Grimme, L. H. Determination of Hydrophobic Parameters for Pyridazinone Herbicides by Liquid/Liquid Partition and Reversed-Phase High-Performance Liquid Chromatography. J. Chromatogr. 1981, 206, 7-15.
29. Vilner, B. J.; de Costa, B. R.; Bowen, W. D. Cytotoxic Effects of Sigma Ligands: Sigma Receptor-Mediated Alterations in Cellular Morphology and Viability. J. Neurosci. 1995, 15, 117-134.
30. Brent, P. J.; Pang, G. T. σ-Binding Site Ligands Inhibit Cell Proliferation in Mammary and Colon Carcinoma Cell Lines and Melanoma Cells in Culture. Eur. J. Pharmacol. 1995, 278, 151-160.
31. 2+ Core. Inorg. Chim. Acta 1984, 90, 41-51.